in co m b i n ation with dissolution dat a , p rovides a rationale for biowa i ver of immediate release ( I R ) d rug prod u ct s.In addition,the Ge n e ral Bi o ava i la b i l i ty and Bi oe q u i va l e n ce guidance (4) allows b i owa i vers for lower strength(s) of immediate release as well as modified release drug prod u ct s based on fo rm u l ation pro po rt i o n a l i ty and dissolution profile co m p a ri s o n .
These changes in bioe q u i va l e n ce re q u i re m e nt s, m oving away from in vivo biostudy re q u i re m e nts in ce rtain cases and relying more on dissolution te s t, c l e a rly establish a change in dissolution test applicat i o n s.In all cases where dissolution test is used as a BE te s t,an anchor with a bioavailable prod u ct is e s t a b l i s h e d.With the evolution and adva n ces in dissolution te c h n o l ogy and the understanding of s c i e ntific principles and mechanism of dissolution test re s u l t s,a clear trend has emerged where dissolution test has moved from traditional quality co nt rol test to a surrog ate in vitro bioe q u i va l e n ce te s t .This re p re s e nts a shift in dissolution thought p rocess and a new re g u l ato ry pe r s pe ct i ve on dissol u t i o n .The dissolution test has moved away fro m t raditional Q C test to a surrog ate in vitro B E te s t (Table 1 ).In seve ral instance s,a biowa i ver is indicated based on dissolution profile co m p a ri s o n .
FDA has adopted a simple mat h e m at i ca l a p p roach for dissolution profile co m p a ri s o n , te rmed similari ty facto r,f 2 ( 1 , 6 , 7 ) .Re g u l ato ry i nte rest is to kn ow how similar the two dissolution p rofile curves are,and for this re a s o n ,the f 2 co m p a rison has been the focus in Ag e n cy guidance s.Wh e n the two profiles are ident i ca l ,f 2 = 100.An ave ra g e issolution testing over the last quarte r ce nt u ry has emerged as a highly va l u a b l e in vitro test to chara cte ri ze drug prod u ct pe rfo rm a n ce.It is an impo rt a nt tool in dru g d eve l o p m e nt and in quality co nt rol ( Q C ). In dru g d eve l o p m e nt it is used to guide fo rm u l ation deve lo p m e nt and to select an appro p ri ate fo rm u l at i o n for in vivo te s t i n g.In quality co nt rol dissolution testing is used as a batc h -to -b atch quality te s t be fo re the prod u ct is released into the marke t p l a ce.For oral solid dosage fo rm s,the dissolution test fo rms the basis for setting spe c i f i cations (te s t, m e t h od o l ogy,a c ce p t a n ce cri te ria) to allow batc h re l e a s e.It is used to identify bioava i l a b i l i ty ( BA ) p roblems and to assess the need for further bioeq u i va l e n ce ( B E ) studies re l at i ve to scale-up and po s t -a p p roval changes ( S U PAC ), w h e re it can function as a signal of bioinequiva l e n ce.At pre s e nt, almost all solid oral dosage fo rms re q u i re dissolution as a Q C test be fo re a prod u ct is int rod u ced into the market place.For the test to be useful,it should be simple,reliable and re p roducible and should be able to discri m i n ate be tween diffe re nt degrees of p rod u ct pe rfo rm a n ce.The value of the test is signifi ca ntly enhanced when prod u ct pe rfo rm a n ce is eva l u ated as a function of time,i . e. ,when the dissolution profile is dete rmined rather than a single po i nt dete rm i n at i o n .Be cause of the impo rt a n ce of d i s s o l u t i o n ,F D A has deve l o ped dissolution re l ate d g u i d a n ces that provide info rm ation and re co mm e n d ations on the deve l o p m e nt of dissolution te s t m e t h od o l ogy,setting dissolution spe c i f i cat i o n s and the re g u l ato ry applications of dissolution testing (1, 2) .
Over the last deca d e,with the increasing kn ow ledge in dissolution scientific principles and mechan i s m s,the dissolution test has turned a new leaf. The dissolution test is used as a surrog ate marke r for bioe q u i va l e n ce te s t,as ev i d e n ced from a re ce nt Bi o p h a rm a ceutics Cl a s s i f i cation Sys tem ( B C S ) g u i da n ce (3).The B C S g u i d a n ce takes into acco u nt thre e major facto r s,d i s s o l u t i o n ,s o l u b i l i ty and inte s t i n a l pe rm e a b i l i ty,t h at gove rn the rate and exte nt of d rug absorption from immediate release solid dosage fo rm s.The B C S p rovides a scientific fra m ewo rk for classifying drug substances based on aqueous solubility and intestinal pe rm e a b i l i ty,a n d D Table 1 .
d i f fe re n ce of 10% at all measured time po i nts results in a f 2 value of 50.F D A has set a public standard for the f 2 value of be tween 50-100 to indicate similari ty be tween two dissolution pro f i l e s,thus implying similar in vivo prod u ct pe rfo rm a n ce.
When dissolution is used as a Q C test for I R p rod u ct s,it is g e n e rally a single po i nt dissolution test and is re p re s e nte d as X % dissolved in Y minute s.Howeve r,when the dissolution test is used as a B E te s t,a dissolution profile is generated for a profile co m p a rison with a bioavailable prod u ct .
The value of dissolution test can be further enhanced in d eveloping co u nt ries where it can be used as a "b i oe q u i val e n ce te s t ." A question to consider is: "Can dissolution te s t alone be used as a B E test for approval of IR prod u cts in d eveloping co u nt ri e s ? " Ge n e rally in developing co u nt ri e s, the te c h n o l ogy and other re s o u rces are ve ry limited to co n d u ct an appro p ri ate in vivo bioe q u i va l e n ce study.Un d e r these circ u m s t a n ce s,a p p ro p ri ate dissolution studies,s u c h a s,p rofile co m p a rison be tween the local generic prod u ct and the re fe re n ce prod u ct in pH 1.2,4.5 and 6.8 media under mild test co n d i t i o n s,b a s ket method at 100 rpm or paddle method at 50 rp m ,m ay be used to assure prod u ct q u a l i ty.This appears to be a pra ct i cal approach that can be easily co n s i d e red and adopted for B E test in deve l o p i n g co u nt ri e s.
In co n c l u s i o n ,in vitro dissolution testing is incre a s i n g l y relied upon to assure prod u ct pe rfo rm a n ce and prod u ct q u a l i ty.The in vitro test proce d u re is a simple and eco n o mi cal method that can be utilized effe ct i vely in deve l o p i n g co u nt ries to assure acceptable drug prod u ct quality.Di s s olution testing is curre ntly used as a Q C te s t,( g e n e rally single po i nt for immediate release prod u cts and 3-to-4 po i nts fo r extended release prod u ct s ) ,as well as an in vitro bioe q u i val e n ce ( B E ) test (generally dissolution profile and pro f i l e co m p a ri s o n ) .Si g n i f i ca n ce of both the tests are diffe re nt,a n d should be ca refully separate d.
